Abstract: A method for determining a productivity of a coalbed methane well without shutting down the well includes steps of: obtaining coalbed methane basic data; based on PVT experimental data, determining a relationship table between a pressure and a coalbed methane deviation factor, and a relationship table between the pressure and a pseudo-pressure; recording daily gas production rates, bottomhole flow pressures, and cumulative gas productions at each stabilized flow pressure test moment in at least three different production stages; determining formation pressures corresponding to each stabilized flow pressure test moment based on a material balance equation; according to the formation pressures, the bottomhole flow pressures and the production rates, determining coefficients in a deliverability equation of the coalbed methane well for determining the deliverability equation; substituting the formation pressures and the bottomhole flow pressures into the deliverability equation for obtaining corresponding product

Abstract: An adsorbent for wastewater treatment includes titanium hexametaphosphate; the titanium hexametaphosphate is mainly prepared from hexametaphosphate and titanium salt. The adsorbent is an aggregate of micron or nanometer particles, with a large surface area and a good adsorption performance. The adsorbent, as a wastewater treatment agent, may effectively remove thallium contaminants in various water bodies such as underground water, surface water, chemical wastewater and mine wastewater at a removal rate of 99.8%; and the adsorbent has a good removal capability for heavy metals in water such as cadmium, plumbum, copper, stibium, cesium and uranium. The adsorbent has a wide applicable PH value range, and especially has a good adsorption capacity, stability and heat resistance under acidic conditions.

Abstract: The disclosure relates to wastewater treatment technologies, and particularly to an adsorbent and its preparation method and application. The adsorbent includes titanium hexametaphosphate; the titanium hexametaphosphate is mainly prepared from hexametaphosphate and titanium salt. The adsorbent is an aggregate of micron or nanometer particles, with a large surface area and a good adsorption performance. The adsorbent, as a wastewater treatment agent, may effectively remove thallium contaminants in various water bodies such as underground water, surface water, chemical wastewater and mine wastewater at a removal rate of 99.8%; and the adsorbent has a good removal capability for heavy metals in water such as cadmium, plumbum, copper, stibium, cesium and uranium. The adsorbent has a wide applicable PH value range, and especially has a good adsorption capacity, stability and heat resistance under acidic conditions. The preparation method is simple to operate, low in reaction condition requirements and low in cost.

Abstract: Provided are a method for the modification of a polypeptide and uses. The method comprises the following steps: (1) introducing an X into the N-terminus of a polypeptide, thereby obtaining X-polypeptide; (2) oxidizing the X into an aldehyde group; (3) adding a reducing agent, and covalently coupling the oxidation product obtained in step (2) with PEG, thereby obtaining a PEG-modified polypeptide, wherein X is threonine or serine. In the present application, a single component of PEG-modified polypeptide is obtained by introducing a threonine or serine into the N-terminus of the polypeptide, and deriving the amino alcohol structure at the ortho-position of the N-terminus of the polypeptide as an aldehyde group by using a high-specificity oxidation method and covalently coupling the aldehyde group with PEG.

Abstract: Related is use of fumaric acid esters or pharmaceutically acceptable salts thereof in preparing a pharmaceutical for treating ferroptosis-related diseases. The fumaric acid esters includes dimethyl fumarate and/or monomethyl fumarate. The present application reveals, for the first time, the effect of fumaric acid ester and its pharmaceutically acceptable salt on a protein level of a ferroptosis key regulatory gene GPX4, provides a theoretical basis for the research of treatment strategies for the ferroptosis-related diseases, and provides a new outlet for preparing pharmaceuticals used for the ferroptosis-related diseases.

Abstract: The disclosure relates to a compound, having a structure of Formula I or a pharmaceutically acceptable salt thereof, herein, R1 is selected from hydrogen, fluorine, and chlorine; R2 and R3 are independently selected from hydrogen, alkyl, a substituted alkyl, alkenyl or a substituted alkenyl, alkynyl or a substituted alkynyl, and aryl, or R2 and R3 are connected to form a ring selected from a cycloalkyl, a substituted cycloalkyl, an aromatic heterocycle or a non-aromatic heterocycle; R4 is selected from hydrogen, cyano, alkyl, a substituted alkyl, alkenyl or a substituted alkenyl, alkynyl or a substituted alkynyl, and aryl; and R5 is selected from hydrogen, halogen, and haloalkyl. The disclosure further relates to a pharmaceutical composition containing the compound. The compound and the composition of the disclosure show significant activity in an aspect of treating AR-prostate cancer and triple-negative breast cancer.

Abstract: The present disclosure provides novel methods for treating cancer and conditions regulatable by a transcription factor and/or cofactor using specific compounds, as well as compositions, and pharmaceutical formulations. In certain embodiments, the compounds are transcription factor modulators.

Abstract: The present disclosure provides novel methods for treating cancer and conditions regulatable by a transcription factor and/or cofactor using specific compounds, as well as compositions, and pharmaceutical formulations. In certain embodiments, the compounds are transcription factor modulators.